Immune Checkpoint Inhibitors Industry Trends: What to Know and Prepare for
Introduction The immune checkpoint inhibitors (ICIs) industry has revolutionized cancer treatment by unleashing the body's immune system to recognize and attack cancer cells. These inhibitors target checkpoint proteins like PD-1, PD-L1, and CTLA-4, which act as "brakes" on the immune system, thereby preventing it from attacking cancerous cells. With notable breakthroughs in immunotherapy, the global market for ICIs has witnessed tremendous growth. As advancements continue to reshape the oncology landscape, understanding the emerging trends in this industry is crucial for stakeholders, including healthcare providers, pharmaceutical companies, investors, and policymakers. The immune checkpoint inhibitors market is estimated to reach a valuation of US$107 billion by the year 2034, at a CAGR of 15%, during the forecast period 2024 to 2034. This article explores the key trends, challenges, and future opportunities in the immune checkpoint inhibitors industry, pro...